Dossier assessment
Lutetium vipivotide tetraxetan (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Lutetium vipivotide tetraxetan (prostate cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Lutetium vipivotide tetraxetan (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
In combination with androgen deprivation therapy with or without androgen receptor pathway inhibition for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy
- Patients for whom abiraterone in combination with prednisone or prednisolone, enzalutamide or best supportive care is the most appropriate therapy for the individual patient: hint of a non-quantifiable added benefit
- Patients for whom cabazitaxel or olaparib is the most appropriate therapy for the individual patient: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-07-06 A G-BA decision was published.
Project details
- Project no.
- A23-01
- Commission
- Commission awarded on 10.01.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Addendum
Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01
Status: Commission completed